✦ LIBER ✦

VASCULAR ENDOTHELIAL GROWTH FACTOR ANTISENSE PRETREATMENT OF BLADDER CANCER CELLS SIGNIFICANTLY ENHANCES THE CYTOTOXICITY OF MITOMYCIN C, GEMCITABINE AND CISPLATIN

✍ Scribed by KRAUSE, S; FORSTER, Y; KRAEMER, K; FUESSEL, S; KOTZSCH, M; SCHMIDT, U; WIRTH, M; MEYE, A; SCHWENZER, B

Book ID: 123509197
Publisher: Lippincott Williams and Wilkins
Year: 2005
Tongue: English
Weight: 265 KB
Volume: 174
Category: Article
ISSN: 0022-5347
DOI: 10.1097/01.ju.0000161588.94827.27

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effect of mitomycin C on concentrations

Effect of mitomycin C on concentrations of vascular endothelial growth factor and its receptors in bladder cancer cells and in bladders of rats intravesically instilled with mitomycin C

✍ Avanti Verma; Justin DeGrado; Adam B. Hittelman; Marcia A. Wheeler; Hristos Z. K 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 425 KB

490 RNA INTERFERENCE (RNAI)-MEDIATED VAS

490 RNA INTERFERENCE (RNAI)-MEDIATED VASCULAR ENDOTHELIAL GROWTH FACTOR-C (VEGF-C) REDUCTION SUPPRESSES MALIGNANT PROGRESSION AND ENHANCES MITOMYCIN C SENSITIVITY OF BLADDER CANCER T24 CELLS

✍ H.H. Zhang; F. Qi; Y.R. Shi; J.G. Miao; M. Zhou; W. He; M.F. Chen; Y. Li; X.B. Z 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 176 KB

828 BCL-XL antisense oligonucleotides as

828 BCL-XL antisense oligonucleotides as an enhancer of the cytotoxic effects of cisplatin, mitomycin C and paclitaxel in the treatment of bladder cancer

✍ A Schaaf; S Sagi; L Trojan; P Alken; M.S Michel 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 192 KB

1153 EFFECT OF MITOMYCIN C ON LEVELS OF

1153 EFFECT OF MITOMYCIN C ON LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS RECEPTORS IN BLADDER CANCER CELLS AND IN BLADDERS OF RATS INTRAVESICALLY INSTILLED WITH MITOMYCIN C

✍ Verma, Avanti; Wheeler, Marcia A.; DeGrado, Justin; Kaimakliotis, Hristos Z.; Hi 📂 Article 📅 2010 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 126 KB

A phase I and pharmacokinetic study of d

A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group

✍ Glenwood Goss; Frances A. Shepherd; Scott Laurie; Isabelle Gauthier; N. Leighl; 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 137 KB